Blurbs

Mizuho Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on BridgeBio Pharma (BBIOResearch Report), with a price target of $23.00. The company’s shares opened today at $10.02.

Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences. According to TipRanks, Syed has an average return of -16.2% and a 33.82% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BridgeBio Pharma with a $23.00 average price target, which is a 129.54% upside from current levels. In a report released on November 3, SVB Securities also reiterated a Buy rating on the stock with a $23.00 price target.

See the top stocks recommended by analysts >>

Based on BridgeBio Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $73.75 million and a GAAP net loss of $9.86 million. In comparison, last year the company earned a revenue of $54.02 million and had a GAAP net loss of $96.35 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Read More on BBIO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More